1 / 26

Epidemiology of RCC: local and worldwide Shouki Bazarbashi King Faisal Specialist Hospital-Riyadh

Epidemiology of RCC: local and worldwide Shouki Bazarbashi King Faisal Specialist Hospital-Riyadh. Number of cancer cases world wide. Estimated Numbers of New Cancer Cases (Incidence) and Deaths (Mortality) in 2007. From Parkin, D. M. et al. CA Cancer J Clin 2008;55:74-108.

helki
Download Presentation

Epidemiology of RCC: local and worldwide Shouki Bazarbashi King Faisal Specialist Hospital-Riyadh

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Epidemiology of RCC: local and worldwideShouki BazarbashiKing Faisal Specialist Hospital-Riyadh

  2. Number of cancer cases world wide

  3. Estimated Numbers of New Cancer Cases (Incidence) and Deaths (Mortality) in 2007 From Parkin, D. M. et al. CA Cancer J Clin 2008;55:74-108.

  4. Estimated Numbers of New Cancer Cases (Incidence) and Deaths (Mortality) in 2007 From Parkin, D. M. et al. CA Cancer J Clin 2008;55:74-108.

  5. Kidney Cancer Incidence: ASR per 100,000 Farley et al, GLOBOCAN 2008

  6. ASR in different countries per 100,000 Saudi arabia

  7. US Yearly Kidney and Renal Pelvis Cancer Incidence SEER data base.

  8. UK Yearly Kidney and Renal Pelvis Cancer Incidence http://www.ons.gov.uk/ons/search/index.html

  9. US Kidney and Renal Pelvis Cancer Incidence and Mortality by Age 60 Incidence 50 Mortality 40 Rate per 100,000 30 20 10 0 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ Age (Years) Ries LAG, et al. SEER Cancer Statistics Review, 1975-2002.

  10. Top 10 cancers KSA, 2009

  11. Top 10 cancers by gender in KSA, 2009

  12. RCC as part of GU cancers in KSAData from 1994- 2006

  13. Kidney cancer in Saudi Arabia 2009CIR and ASR

  14. Kidney cancer in certain age groups, Saudi Arabia 2009 data

  15. Number of cases by age group

  16. RCC in Saudi Arabia: incidence trend* * ASR per 100,000 population

  17. Number of RCC cases in last 8 reports

  18. Histological subtypes2000-2005, 738 pts.

  19. Distribution according to region2000-2005, 738 pts.

  20. Risk factors Smoking Occupational exposure; asbestos, petrochemical products Obesity Acquired cystic disease of the kidney Genetic factors Alcohol

  21. Autosomal dominant forms of kidney cancer VHL: von Hippel-Lindau; HPRC: hereditary papillary renal carcinoma; HLRCC: hereditary leiomyomatosis renal cell carcinoma FH: fumarate hydratase; BHD: Birt-Hogg-Dubé syndrome

  22. Summary RCC is an uncommon disease with global incidence of 2.5-4.7 /100,000. Incidence in Saudi Arabia is much lower at ˂ 3/100,000 Incidence is highest in the west and lowest in south east Asia RCC incidence increase with age. Peak incidence appears at an earlier age in KSA than the western world Despite increasing incidence world wide, mortality rate is stable, probably indicating detecting more early cases Clear cell histology represent the majority of cases in Saudi Arabia

  23. Back up slides

  24. Kidney Cancer Incidence and MortalityAP GLOBOCAN 2002, IARC *Hong Kong Cancer Registry 2006 ** Taiwan Cancer Registry, 1995

  25. Kidney Cancer and Renal Cell Carcinoma Kidney cancer Renal cell carcinoma: 90% Transitional cell carcinomas: 5-10% Wilms tumors: 5% Renal sarcomas: rare Renal cell carcinoma Internationally, incidence rates vary by up to 10-fold Highest in developed countries Worldwide, incidence rates increased by 2% per year over the past 65 years Peak incidence between 60 and 70 years Frequent metastasis sites: Lung (50-60%), bone (30-40%), liver (30-40%), brain (5%)

  26. Renal Cell Carcinoma For mRCC: Median survival: 10.9-26.4 months 20%-30% of patients present with mRCC 20%-40% of patients will develop mRCC after nephrectomy Increasing disease severity

More Related